Valuation: Novartis AG

Market Cap 290B 250B 235B 214B 402B 27,689B 407B 2,750B 1,077B 13,872B 1,087B 1,064B 46,146B P/E 2026 *
21.6x
P/E 2027 * 18.5x
Enterprise Value 323B 279B 261B 238B 448B 30,856B 454B 3,064B 1,201B 15,459B 1,212B 1,185B 51,422B EV / Sales 2026 *
5.59x
EV / Sales 2027 * 5.18x
Free-Float
91.66%
Yield 2026 *
2.87%
Yield 2027 * 2.99%
1 day-0.02%
1 week-3.85%
Current month-3.86%
1 month-3.55%
3 months+2.35%
6 months-6.79%
Current year+10.32%
1 week 128.92
Extreme 128.92
133.92
1 month 128.92
Extreme 128.92
140.82
Current year 116
Extreme 116
144.12
1 year 103.16
Extreme 103.16
144.12
3 years 94
Extreme 94
144.12
5 years 94
Extreme 94
144.12
10 years 61.7
Extreme 61.7
144.12
Manager TitleAgeSince
Chief Executive Officer 50 31/01/2018
Director of Finance/CFO - 15/03/2026
Compliance Officer 58 13/04/2025
Director TitleAgeSince
Director/Board Member 67 31/12/2014
Director/Board Member 69 31/12/2015
Director/Board Member 61 31/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%-3.85% - - 290B
+0.25%-3.96%+68.73%+120.06% 1,055B
+0.78%+0.21%+48.53%+50.78% 632B
+0.35%+0.95%+21.11%+66.86% 442B
+0.28%-4.56%+39.10%+38.05% 351B
+0.78%-2.68%+24.03%+37.32% 290B
+0.87%-3.59%-0.28%+7.12% 243B
+1.00%+0.52%+41.46%+58.95% 227B
-0.78%-4.49%-10.28%-54.13% 200B
+0.40%+4.40%+17.36%+81.59% 172B
Average +0.39%-1.44%+27.75%+45.18% 401.39B
Weighted average by Cap. +0.41%-1.87%+39.71%+63.88%

Financials

2026 *2027 *
Net sales 57.71B 49.82B 46.74B 42.57B 80.04B 5,517B 81.15B 548B 215B 2,764B 217B 212B 9,195B 61.25B 52.88B 49.61B 45.19B 84.96B 5,857B 86.14B 582B 228B 2,934B 230B 225B 9,760B
Net income 13.95B 12.04B 11.3B 10.29B 19.35B 1,334B 19.62B 132B 51.9B 668B 52.38B 51.24B 2,223B 15.5B 13.38B 12.56B 11.44B 21.5B 1,482B 21.8B 147B 57.67B 743B 58.2B 56.94B 2,470B
Net Debt 33.11B 28.59B 26.82B 24.43B 45.93B 3,166B 46.57B 314B 123B 1,586B 124B 122B 5,277B 27.82B 24.01B 22.53B 20.52B 38.58B 2,660B 39.12B 264B 103B 1,333B 104B 102B 4,433B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
13/08/26 130.44 -1.26% 2,054
17/08/26 €131.26 +0.63% 1,425
14/08/26 €130.44 -1.26% 2,054
13/08/26 €132.10 -0.72% 2,795
12/08/26 €133.06 -1.20% 1,476
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
152.36USD
Average target price
154.18USD
Spread / Average Target
+1.19%

Quarterly revenue - Rate of surprise